Cantor Fitzgerald Forecasts Stronger Earnings for Immunocore

Immunocore Holdings plc (NASDAQ:IMCR) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Immunocore in a research report issued to clients and investors on Thursday, May 8th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($0.52) per share for the year, up from their prior estimate of ($1.42). The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period last year, the company posted ($0.49) EPS.

Other analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, April 14th. Oppenheimer increased their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and set a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. Finally, Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.13.

Immunocore Stock Performance

IMCR opened at $28.55 on Monday. Immunocore has a twelve month low of $23.15 and a twelve month high of $58.36. The firm has a market capitalization of $1.43 billion, a PE ratio of -30.05 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm’s 50-day moving average price is $28.75 and its 200 day moving average price is $30.10.

Insider Activity

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 10.40% of the company’s stock.

Institutional Trading of Immunocore

A number of hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its position in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after buying an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in Immunocore by 125.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after acquiring an additional 27,598 shares during the last quarter. Crossmark Global Holdings Inc. raised its holdings in shares of Immunocore by 36.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock worth $1,121,000 after purchasing an additional 10,217 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after purchasing an additional 960 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Immunocore by 5.3% during the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after purchasing an additional 1,616 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.